DADina Essam Abo-Elnour

Dina Essam Abo-Elnour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dina Essam Abo-Elnour has a total of 194 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Contributors

    by Abdallah Abbas, Celine Abboud, Ashrakt H. Abdelhamid, Dina Essam Abo-Elnour, Moaz Elsayed Abouelmagd, Esther Abosede Adewumi, Lila Agbaria, Mohamed Abdelsattar Ahmed, Md Anzar Alam, Gideon S. Alex, et al.

  • Artificial intelligence and machine learning in Parkinson's drug development: Virtual reality and gamification

    by Mahmoud Tarek Hefnawy, Kholoud Elsamman, Khaled Moghib, Dina Essam Abo-Elnour, Ossama Doubie, Hager Adel Saad, Mohamed Shih, Ahmed Fathy Said Shelan, Abdallah Abbas

  • Efficacy and safety of tolebrutinib in multiple sclerosis: a systematic review and meta-analysis

    by Nada Mosad, Yara Roshdy, Tasbih Emad, Ahmed Harb, Dina Essam Abo-Elnour, Yasein Fadel Awadalla, Woroud AL Fauomi, Asmaa Zakria Alnajjar

    Background Tolebrutinib is an oral, brain-penetrant Bruton’s tyrosine kinase (BTK) inhibitor being investigated for multiple sclerosis (MS). Early data point to reduced relapse rates and radiological disease activity, along with a reassuring safety profile. This systematic review and meta-analysis bring together the available evidence on its clinical efficacy and adverse events. Methods We searched PubMed, Web of Science, and Scopus through February 2026 using predefined eligibility criteria. Data were extracted on efficacy outcomes (disability progression and improvement, MRI activity, and brain volume change) and safety outcomes (any adverse events, serious adverse events, adverse events leading to discontinuation, headache, ALT elevation, and death). Continuous outcomes were pooled as means using reported means and standard deviations; proportional outcomes were pooled from event and total counts. Analyses were run in R using random-effects models, with data unsuitable for pooling described narratively. Results Four publications met our inclusion criteria: three reporting four randomized controlled trials and one long-term extension study. Tolebrutinib reduced the risk of confirmed disability progression at both ≥3 and ≥6 months, and disability improvement at 6 months was numerically higher than with comparators, though not conclusively so. Pooled progression rates were 18.35% (95% CI 9.73–31.9) at ≥3 months and 14.08% (95% CI 6.78–26.95) at ≥6 months. Mean brain volume change was -0.69% (95% CI -0.73 to -0.65). Adverse events of any kind occurred in 75.98% of patients, serious adverse events in 11.26%, and discontinuation due to adverse events in 4.14%; deaths were rare. Conclusion The available trial evidence suggests that tolebrutinib may reduce confirmed disability progression in nonrelapsing secondary progressive MS and MRI inflammatory activity versus placebo in earlier-phase relapsing MS. These findings are preliminary and should not be interpreted as definitive comparative evidence; longer-term, adequately powered studies are needed to define durability, safety, and its place relative to established disease-modifying therapies.

  • Open Access

    Safety and efficacy of tirofiban as an adjunct to endovascular thrombectomy in large vessel occlusion stroke: A systematic review and meta-analysis with GRADE assessment

    by Mostafa Hossam El Din Moawad, Dina Essam Abo-Elnour, Yasmine M. Osman, Mohamed Hendawy, Muhammad Daoud Tariq, Ahmed Hassan A. Rady, Anfel Rahai, Ahmed Abdullah Abo Elnaga, Ibrahim Serag, Ibraheem M. Alkhawaldeh, et al.

  • Open Access

    Efficacy and safety of repetitive transcranial magnetic stimulation in anorexia and bulimia nervosa: a systematic review and meta-analysis

    by Dalia Kamal Ewis, Haneen Sabet, Yousef Hawas, Wajeeh Hassan, Moaz Elsayed Abouelmagd, Arwa Jader, Dina Essam Abo-Elnour, Abdallah Abbas, Mohamed E. G. Elsayed, Carlos Schönfeldt-Lecuona, et al.

    Objective: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with anorexia nervosa (AN) and bulimia nervosa (BN), focusing on its impact on psychological, psychopathological, neurocognitive, and behavioral outcomes. Methods: A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Cochrane CENTRAL from inception to May 2025. Eligible studies included clinical trials involving adult patients with AN or BN treated with rTMS. Data were pooled using fixed or random-effects models depending on heterogeneity. Mean differences (MD) or standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated. Risk of bias was assessed using Cochrane RoB 2.0 and NIH tools. Results: Thirteen studies were included, yielding a total of n = 195 active rTMS treatments and n = 132 sham treatments. Compared to sham, rTMS did not significantly improve BMI in AN patients (MD: 0.19; 95% CI: -0.50, 0.88; P = 0.59). A significant moderate reduction in eating disorder severity was found in single-arm analysis (31 patients, SMD: -0.50, 95% CI [-0.90, -0.10], p = 0.01). Depression improved with rTMS over sham (105 patients, SMD: -0.41, 95% CI [-0.81, -0.02], p = 0.04), while anxiety, binge frequency, and vomiting frequency did not. Urge to eat increased in AN (30 patients, MD: 1.20, 95% CI [0.20, 2.21], p = 0.02) and decreased in BN (25 patients, MD: -10.25, 95% CI [-15.88, -4.62], p = 0.0004). No serious adverse events were reported. Conclusions: rTMS shows potential in improving eating disorder severity and depressive symptoms in AN, with disorder-specific modulation of food-related urges. Its effects on BMI and behavioral symptoms remain inconclusive. rTMS was well tolerated.

  • Open Access

    The Viloxazine Paradox: A Noradrenergic Agent's Journey From Antidepressant Obscurity to ADHD Precision Therapy

    by Ghaith K. Mansour, Sabry Babiker H. Sayed, Sajjad Ghanim Al‐Badri, Mohammed Gamaleldin Abdulrahim Abdalla, Dina Essam Abo‐Elnour

    Aims: Viloxazine is a serotonin–norepinephrine modulatory agent that was recently approved by the U.S. Food and Drug Administration for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. This review aims to summarize the regulatory history, pharmacology, pharmacokinetics, clinical efficacy, safety, and current therapeutic role of viloxazine, while also highlighting gaps in the evidence and future research directions. Methods: A narrative literature review was conducted using PubMed, Google Scholar, and FDA regulatory documents. Relevant peer‐reviewed articles, including clinical trials, reviews, meta‐analyses, and prescribing information, were screened for data on viloxazine's historical antidepressant use, mechanism of action, pharmacokinetics, efficacy in ADHD, safety profile, drug interactions, and comparative effectiveness. Non‐peer‐reviewed sources were excluded. Results: Viloxazine was originally marketed in Europe in the 1970s as an antidepressant and showed a favorable safety profile over decades of use. Its pharmacological profile includes moderate norepinephrine reuptake inhibition with additional serotonergic activity, particularly 5‐HT2C agonism and 5‐HT2B antagonism, which supported its repurposing as an extended‐release formulation for ADHD. Multiple randomized, placebo‐controlled trials demonstrated that viloxazine extended‐release significantly improves ADHD symptoms in pediatric, adolescent, and adult populations. Reported effect sizes were generally smaller than those of stimulants but comparable to atomoxetine. The most common adverse events were somnolence, headache, nausea, decreased appetite, and insomnia. Viloxazine also has a pharmacokinetic profile compatible with once‐daily dosing, although clinically relevant drug interactions may occur through CYP1A2 inhibition. Conclusion: Viloxazine expands the range of non‐stimulant treatment options for ADHD and represents a successful example of drug repurposing in neuropsychiatry. Current evidence supports its efficacy and acceptable tolerability across the lifespan, particularly for patients who do not tolerate or respond adequately to stimulants. Nevertheless, evidence for its use beyond ADHD remains limited, and future studies should focus on head‐to‐head comparisons with other ADHD therapies, long‐term safety and efficacy, predictors of response, and potential off‐label psychiatric applications.

  • Effectiveness and safety of intravenous thrombolysis for non-arteritic central retinal artery occlusion: A GRADE-assessed meta‐analysis

    by Abdallah Abbas, Haneen Sabet, Dina Essam Abo-Elnour, Jude Al-Mufti, Majed Aldehri, Ibrahim Alnaami, Thanh N. Nguyen

  • Alteplase versus tenecteplase in acute ischemic stroke with large vessel occlusion: a systematic review and meta-analysis

    by El Din Moawad, Mostafa Hossam, Ibrahim Serag, Abo Elnaga, Ahmed A., Dina Essam Abo-Elnour, Hamza A. Abdul-Hafez, Mohamed Ahmed Hammad, Lobna Ahmed Mohamed, Rawan Kamal Mohamed, et al.

    Background Intravenous thrombolysis remains a cornerstone in acute ischemic stroke (AIS) management, particularly in large vessel occlusion (LVO). While alteplase has long been the standard thrombolytic agent, tenecteplase has emerged as a promising alternative due to its pharmacokinetic advantages. This systematic review and meta-analysis aim to compare the efficacy and safety of tenecteplase versus alteplase in AIS patients with LVO. Methods A systematic search was conducted across PubMed, Scopus, Web of Science, Cochrane Library, and Embase until February 2025. Studies comparing tenecteplase and alteplase in AIS patients with LVO were included. The primary outcomes were functional independence at 3 months (modified Rankin Scale [mRS] 0–1 and 0–2), mortality, and symptomatic intracranial hemorrhage (sICH). Secondary outcomes included any bleeding, adverse events, and overall complications. Pooled estimates were calculated using risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). Results A total of 14 studies (N = 9641 patients) were included, comprising 5898 patients receiving alteplase and 3743 receiving tenecteplase. No significant differences were observed in 3-month functional outcomes: mRS 0–1 (RR = 0.92, 95% CI: 0.78 to 1.1, P = 0.38) and mRS 0–2 (RR = 0.95, 95% CI: 0.83 to 1.08, P = 0.44). Mortality rates were comparable between groups (OR = 1.07, 95% CI: 0.88–1.30). No significant differences were found in intracranial hemorrhage (ICH) (OR = 1.25, 95% CI: 0.96–1.62), sICH (OR = 1.1, 95% CI: 0.91–1.33), or any bleeding (OR = 1.19, 95% CI: 0.9–1.57). The pooled OR for adverse events was 0.79 (95% CI: 0.53 to 1.17), indicating a comparable safety profile. Conclusion This meta-analysis supports the non-inferiority of tenecteplase compared to alteplase in LVO-associated AIS regarding efficacy and safety. While tenecteplase offers practical advantages, including single-bolus administration and potentially lower costs, further large-scale randomized controlled trials are needed to confirm these findings and optimize thrombolytic selection in stroke care.


  • Open Access

    Etiology-specific optimal timing of surgical intervention for intracranial hemorrhage: a systematic review and network meta-analysis

    by Nada Mostafa Al-Dardery, Dina Essam Abo-Elnour, Sadil Mohammad Bani Khaled, Alyaa Khaled Madeeh, Shahd Alqato, Suhel.F. Batarseh, Mariam A. Abusalah, Amr Diaaeldin Sayed Mahmoud, Wesal Nasr Mahmoud, Abdulrhman M Khaity

    Background: Intracranial hemorrhages (ICrH), including intracerebral hemorrhage (ICH) and aneurysmal subarachnoid hemorrhage (aSAH), are life-threatening conditions leading to high mortality and long-term disability. A persistent challenge in clinical practice is identifying the most advantageous timing for surgical intervention, as existing literature reveals conflicting outcomes regarding survival, neurological recovery, and complication rates. The literature remains heterogeneous despite extensive research, presenting conflicting evidence regarding survival benefits across various surgical timeframes, from ultra-early interventions (7 days). This study aimed to determine the optimal timing for surgery in intracranial bleeding by comparing outcomes across timeframes to guide evidence-based clinical decisions. Methods: A systematic search of PubMed, Scopus, Web of Science, and Cochrane Library was conducted for studies published from 2000 to 2025. Twenty-eight observational studies, including 5919 patients, were included. Data were analyzed using random-effects models in R software, with subgroup analyses based on the time windows and type of hemorrhage. Results: Surgery performed within 24 hours significantly reduced the odds of poor GOS scores (OR: 0.53, 95% CI: 0.31–0.92) and rebleeding (OR: 0.55, 95% CI: 0.37–0.80). The network meta-analysis indicated that surgery within 48 hours is the most effective timing for reducing mortality ( P -score = 0.99). However, pairwise comparisons revealed non-significant effects (OR = 0.94, 95% CI: 0.51–1.72), underscoring the necessity for etiology-specific interpretation. Early intervention (≤72 hours) was most beneficial in aSAH, whereas ultra-early surgery (<6 hours) in traumatic ICH showed higher mortality. Surgery delayed beyond 7 days resulted in worse functional recovery. Conclusions: Early surgical intervention, particularly within 24–48 hours, improves outcomes in many cases of ICH. However, optimal timing varies with hemorrhage type. The findings resolve previous discrepancies by illustrating that treatment effects are contingent upon both the timeframe and the underlying pathology. Personalized timing strategies are essential, and further high-quality randomized trials are needed to refine clinical guidelines.


  • Comprehensive bibliometric analysis of characteristics, patterns, and causes of retractions in pediatric literature

    by Dina Essam Abo-Elnour, Mohamed Mohsen Helal, Abdulrahman Ahmed Albalasy, Hamza A. Abdul-Hafez, Ahmed Abdelkader, Eman Raafat El-Sherbini, Yomna Emad Abdalla, Salma Tamer Abdelrahman, Asmaa G. Salem, Menna M. Sarhan, et al.

    This study aimed to systematically identify the key characteristics of retracted articles in pediatric literature and explore the patterns and reasons of pediatric retraction from 1995 to 2024. We searched PubMed and Retraction Watch databases to identify all retracted publications in the field of pediatrics. After the screening process, data were extracted into Excel. Statistical analysis was conducted using Jamovi and Excel. A correlation matrix was used for the important retraction-related factors. After screening, 590 unique retracted pediatric articles were included, with most of them, 572 (96.9%), having retraction notices available; 516 (87.5%) published as open access; 433 (73.4%) from Asia—mostly China; 348 (59%) retracted by the publisher; 301 (51.0%) published by Hindawi; 275 (46.6%) observational studies; and 221 (37.5%) retracted due to misconduct. Articles with four authors showed the highest retraction rate, and the retraction rate generally decreased as the number of authors increased. Most retractions occurred in 2023. The most common pediatric age group included in the retracted papers was children. The median H-index of authors of retracted papers was 8 for first authors and 10 for senior authors. The median time from submission to acceptance of retracted papers was 50 days and that from publication to retraction was 15 months. Additionally, time to retraction was positively correlated with the journal’s impact factor (r = 0.106, p = 0.015) and the citation count (r = 0.213, p < 0.001) but showed no significant correlation with time to acceptance (r = − 0.019, p = 0.675). Conclusion: The increasing number of retracted pediatric papers reflects a growing concern with a complex pattern and various determinants. Researchers and publishers should adopt strong regulations and guidelines to improve the integrity of scientific research, especially pediatric research. What is Known: • Retractions in biomedical research have been increasing over the past decades, often due to research misconduct, plagiarism, or data fabrication. • Previous studies have analyzed retraction patterns across several medical specialties, but pediatric research remains underexplored despite its ethical and clinical sensitivity. What is New: • This is the most comprehensive analysis of retracted publications in pediatric literature, covering 590 articles from 1995 to 2024 and revealing distinct geographic, temporal, and publisher- and author-related patterns. • The study highlights a strong dominance of retractions from Asia—especially China—and shows that research misconduct and peer-review manipulation are the leading causes, underscoring the urgent need for stricter integrity measures in pediatric research.